Media coverage about Kindred Biosciences (NASDAQ:KIN) has been trending positive recently, Accern reports. The research group identifies negative and positive news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Kindred Biosciences earned a news sentiment score of 0.27 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 44.9358942640393 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Kindred Biosciences (NASDAQ KIN) traded up $0.20 during trading hours on Monday, reaching $8.20. The company’s stock had a trading volume of 106,100 shares, compared to its average volume of 74,879. Kindred Biosciences has a 52 week low of $5.00 and a 52 week high of $9.80. The company has a market cap of $231.10, a P/E ratio of -7.01 and a beta of 0.07.

A number of research firms have commented on KIN. Zacks Investment Research raised Kindred Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, January 13th. BMO Capital Markets reaffirmed a “hold” rating on shares of Kindred Biosciences in a report on Friday, December 22nd. B. Riley set a $11.00 target price on Kindred Biosciences and gave the stock a “buy” rating in a report on Tuesday, December 5th. CL King began coverage on Kindred Biosciences in a report on Wednesday, December 27th. They set a “neutral” rating on the stock. Finally, ValuEngine raised Kindred Biosciences from a “sell” rating to a “hold” rating in a report on Friday, December 1st. Four equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $9.63.

In other Kindred Biosciences news, Director Raymond Townsend sold 6,419 shares of the stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $9.45, for a total transaction of $60,659.55. Following the transaction, the director now owns 18,419 shares of the company’s stock, valued at approximately $174,059.55. The transaction was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 19.10% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Kindred Biosciences (KIN) Receives News Impact Score of 0.27” was first published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this article on another publication, it was stolen and republished in violation of United States and international copyright & trademark legislation. The legal version of this article can be accessed at https://theolympiareport.com/2018/02/12/kindred-biosciences-kin-receives-news-impact-score-of-0-27.html.

Kindred Biosciences Company Profile

Kindred Biosciences, Inc is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products.

Insider Buying and Selling by Quarter for Kindred Biosciences (NASDAQ:KIN)

Receive News & Ratings for Kindred Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.